Diazepam (Valtoco) vs Staccato Alprazolam

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Diazepam (Valtoco)

Marketed by Neurelis, Inc.

Approved in Epilepsysmall molecule
Weak signal

NCT02721069 · Phase 3 · completed

The study was open-label, nonrandomized, and had no placebo or active comparator, so it provides uncontrolled safety and treatment-exposure information rather than comparative evidence of effectiveness. Its primary endpoint was the number of participants receiving NRL-1 over 12 months, not a hard clinical seizure outcome, and no formal primary-endpoint comparison was applicable.

Next expected readout: December 2026 · NCT06346262 (registry estimate)

Reported efficacy

Number of Participants Who Received NRL-1 (Valtoco) (12 months): Number of Participants Who Received NRL-1 (Valtoco) (12 months): NRL-1 5mg 9 Participants | NRL-1 10mg 54 Participants | NRL-1 15 mg 46 Participants | NRL-1 20mg 54 Participants (not_applicable)

Result source: NCT02721069

Staccato Alprazolam

Developed by UCB and partners

Phase 3 in Epilepsysmall molecule
Reliable signal

NCT03478982 · Phase 2 · completed

The study randomized participants to Staccato alprazolam or matching placebo and was described as quadruple-blind, with 156 participants enrolled and 38, 38, and 40 participants in the evaluable 1.0-mg, 2.0-mg, and placebo groups, respectively. Its primary clinical endpoint—seizure cessation within 2 minutes without recurrence for 2 hours—was statistically significantly better with both alprazolam doses than with placebo.

Next expected readout: March 2027 · NCT05077904 (registry estimate)

Reported efficacy

Percentage of Participants in Each Treatment Group Achieving Seizure Activity Cessation Within 2 Minutes and no Recurrent Seizure Within 2 Hours (2 hours post-dosing on dosing day): 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8) (met)

Result source: NCT03478982

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDiazepam (Valtoco)Staccato Alprazolam
Seizure frequency, % change—Not reported—Trial running · NCT05076617
50% responder rate—Not reported—Trial running · NCT05076617
Seizure freedom—Not reported—Trial running · NCT05076617

Seizure frequency, % change

Diazepam (Valtoco)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617

50% responder rate

Diazepam (Valtoco)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617

Seizure freedom

Diazepam (Valtoco)
—Not reported
Staccato Alprazolam
—Trial running · NCT05076617
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Diazepam (Valtoco): 3 of 4 rows · Staccato Alprazolam: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDiazepam (Valtoco)Staccato Alprazolam
Dropout rate
—20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
—15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
5.3%
NCT02724423 · Phase 1 · registry result, not featured evidence
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
0%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Discontinued due to AEs
—20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
—15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
—
NCT02724423 · Phase 1 · registry result, not featured evidence
—2.0 mgb
NCT03478982 · Phase 2
show 2 more results
—1.0 mg
NCT03478982 · Phase 2
—1.0 mg
NCT03478982 · Phase 2
Serious AEs
24.1%20mga
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
32.6%15mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
37%10mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
22.2%5mg
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
1.8%
NCT02724423 · Phase 1 · registry result, not featured evidence
0%2.0 mgb
NCT03478982 · Phase 2
show 2 more results
2.6%1.0 mg
NCT03478982 · Phase 2
0%1.0 mg
NCT03478982 · Phase 2
Most frequent reported AEs
20mga
nasal discomfort 11.1%
nasopharyngitis 7.4%
upper respiratory tract infection 7.4%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
show 4 more results
15mg
seizure 15.2%
upper respiratory tract infection 15.2%
nasal discomfort 8.7%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
10mg
nasopharyngitis 22.2%
pyrexia 18.5%
upper respiratory tract infection 16.7%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
5mg
influenza 33.3%
diarrhoea 22.2%
nasopharyngitis 11.1%
NCT02721069 · Phase 3 · monotherapy · Epilepsy · phase 3
dysgeusia 5.3%
nasal discomfort 3.5%
nasopharyngitis 3.5%
NCT02724423 · Phase 1 · registry result, not featured evidence
2.0 mgb
cough 18.4% (placebo 0%)
dysgeusia 10.5% (placebo 2.5%)
somnolence 10.5% (placebo 2.5%)
NCT03478982 · Phase 2
show 2 more results
1.0 mg
somnolence 18.4% (placebo 2.5%)
dysgeusia 15.8% (placebo 2.5%)
cough 10.5% (placebo 0%)
NCT03478982 · Phase 2
1.0 mg
cough 12.5% (placebo 0%)
dysmenorrhoea 12.5% (placebo 0%)
gastroenteritis viral 12.5% (placebo 0%)
NCT03478982 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Staccato Alprazolam

Seizure Cessation 2min no Recurrence 2 h 65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
62.5% (n=8) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
65.8% (n=38) vs 42.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Rescue Medication Use 7.9% (n=38) vs 7.5% (n=40) placebo @ 0.01wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
0% (n=8) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
15.8% (n=38) vs 7.5% (n=40) placebo @ 0.01wk1.0 mg
NCT03478982 · Phase 2
Secondary Generalization 0% (n=38) vs 0% (n=40) placebo @ 0.14wk2.0 mg
responder rate · % of participants
NCT03478982 · Phase 2
show 2 more results
12.5% (n=8) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2
0% (n=38) vs 0% (n=40) placebo @ 0.14wk1.0 mg
NCT03478982 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valtoco)'s landscape · Staccato Alprazolam's landscape